

Supplementary Online Content

eTable 1. Comorbidities, n/N (%)

eTable 2. Post-vaccination Symptoms After First BNT162b2 Vaccine Dose, n/N (%)

eTable 3. Post-vaccination Symptoms After Second BNT162b2 Vaccine Dose, n/N (%)

eTable 4. Post-vaccination Symptoms After Third BNT162b2 Vaccine Dose, n/N (%)

eTable 5. Post-vaccination Symptoms After Fourth BNT162b2 Vaccine Dose, n/N (%)

eTable 6. Post-vaccination Symptoms After Fifth BNT162b2 Vaccine Dose, n/N (%)

eTable 7. Post-vaccination Symptoms After Sixth BNT162b2 Vaccine Dose, n/N (%)

eTable 8. Local Symptoms

eTable 9. General Symptoms

eTable 10. Musculoskeletal Symptoms

eTable 11. Gastrointestinal Symptoms

eTable 12. Otolaryngological Symptoms

eTable 13. Pulmonary Symptoms

eTable 14. Cardiovascular Symptoms

eTable 15. Neurological Symptoms

eTable 16. Psychological Symptoms

eTable 17. Dermatological Symptoms

eTable 18. Post-vaccination Symptoms After Monovalent and Bivalent BNT162b2 n/N (%)

eTable 19. Active Comparator Analysis, Over All Age groups 0-17 years, n/N (%)

eTable 20. Serious Adverse Events (SAE) and Characteristics of children with reported SAE after BNT162b2 Vaccination, n/N (%)

eTable 21. Characteristics of children with reported Hospitalisation after BNT162b2 Vaccination, n/N (%)

eTable 22. Counts of Missing Data, n/N (%)

eTabel 1. Comorbidities, n/N, %

	All
Comorbidities, all	396/3228 (12.3)
Pulmonary	120/3228 (3.7)
Oncological	2/3228 (0.1)
Rheumatological	15/3228 (0.5)
Gastrointestinal	23/3228 (0.7)
Cardiovascular	53/3228 (1.6)
Immunosuppression	6/3228 (0.2)
Chromosomal aberration	37/3228 (1.1)
Other comorbidities	207/3228 (6.4)
Long-Term medication. Total	246/3228 (7.6)
Analgetics	9/3228 (0.3)
Antibiotics	4/3228 (0.1)
Immunosuppressants	7/3228 (0.2)
Diuretics	3/3228 (0.1)
Inhalatives	67/3228 (2.1)
Anticonvulsants	6/3228 (0.2)
Aniticoagulants/ platelet aggregation inhibitors	10/3228 (0.3)
Other medications	178/3228 (5.5)

eTable 2. Post-vaccination Symptoms After First BNT162b2 Vaccine Dose, n/N (%)

	Female ¹	Male	0-23 months			2-4 years			5-11 years			12-17 years		
Symptoms/ Dosage			Unk.	>3 µg	≤3 µg	Unk.	>3 µg	≤ 3µg	Unk.	> 10µg	≤ 10 µg	Unk.	> 30µg	≤ 30µg
Local	850/1592 (53.4)	758/1580 (48.0)	0/3 (0.0)	90/301 (29.9)	41/100 (41.0)	4/13 (30.8)	360/826 (43.6)	67/160 (41.9)	160/303 (52.8)	46/70 (65.7)	597/1020 (58.5)	75/113 (66.4)	0/0 (0.0)	157/240 (65.4)
General	301/1586 (19.0)	262/1570 (16.7)	0/3 (0.0)	40/300 (13.3)	11/99 (11.10)	1/13 (7.7)	110/819 (13.4)	18/159 (11.3)	59/303 (19.5)	18/70 (25.7)	179/1013 (17.7)	35/113 (31.0)	0/0 (0.0)	89/241 (36.9)
Fever	103/1609 (6.4)	92/1594 (5.8)	0/3 (0.0)	20/303 (6.6)	7/101 (6.9)	0/13 (0.0)	46/831 (5.5)	8/161 (5.0)	19/300 (6.2)	7/71 (9.9)	51/1028 (5.0)	10/114 (8.8)	0/0 (0.0)	26/245 (10.6)
Musculoskeletal	86/1575 (5.5)	75/1569 (4.8)	0/3 (0.0)	2/300 (0.7)	1/100 (1.0)	0/13 (0.0)	24/816 (2.9)	4/157 (2.5)	21/302 (7.0)	7/70 (10.0)	56/1012 (5.5)	18/110 (16.4)	0/0 (0.0)	27/238 (11.3)
Gastrointestinal	24/1573 (1.5)	15/1565 (1.0)	0/3 (0.0)	6/300 (2.0)	1/100 (1.0)	0/13 (0.0)	13/815 (1.6)	0/159 (0.0)	5/301 (1.7)	0/69 (0.0)	11/1007 (1.1)	1/111 (0.9)	0/0 (0.0)	2/238 (0.8)
Otolaryngological	12/1567 (0.8)	11/1511 (0.7)	0/3 (0.0)	0/298 (0.0)	0/100 (0.0)	0/12 (0.0)	4/812 (0.5)	0/158 (0.0)	3/297 (1.0)	0/70 (0.0)	9/1010 (0.9)	3/110 (2.7)	0/0 (0.0)	4/234 (1.7)
Pulmonary	8/1574 (0.5)	9/1563 (0.6)	0/3 (0.0)	2/299 (0.7)	0/100 (0.0)	0/13 (0.0)	5/816 (0.6)	0/158 (0.0)	0/298 (0.0)	0/70 (0.0)	5/1010 (0.5)	2/111 (1.8)	0/0 (0.0)	3/237 (1.3)
Cardiovascular	11/1572 (0.7)	10/1561 (0.6)	0/3 (0.0)	0/298 (0.0)	0/100 (0.0)	0/13 (0.0)	2/813 (0.2)	0/158 (0.0)	3/300 (1.0)	1/70 (1.4)	7/1009 (0.7)	2/111 (1.8)	0/0 (0.0)	6/236 (2.5)
Neurological	76/1571 (4.8)	63/1558 (4.0)	0/3 (0.0)	0/297 (0.0)	0/98 (0.0)	0/13 (0.0)	14/815 (1.7)	1/158 (0.6)	15/298 (5.0)	10/70 (14.3)	56/1008 (5.6)	9/111 (8.1)	0/0 (0.0)	32/236 (13.6)
Psychological	18/1573 (1.1)	6/1558 (0.4)	0/3 (0.0)	4/298 (1.3)	0/100 (0.0)	0/13 (0.0)	3/813 (0.4)	0/158 (0.0)	3/298 (1.0)	1/69 (1.4)	8/1010 (0.8)	1/111 (0.9)	0/0 (0.0)	4/236 (1.7)
Dermatological	30/1570 (1.9)	23/1555 (1.5)	0/3 (0.0)	3/298 (1.0)	1/100 (1.0)	0/13 (0.0)	9/810 (1.1)	3/158 (1.9)	5/298 (1.7)	3/70 (4.3)	21/1006 (2.1)	1/111 (0.9)	0/0 (0.0)	5/236 (2.1)

¹and sex category *diverse*

eTable 3. Post-vaccination Symptoms After Second BNT162b2 Vaccine Dose, n/N (%)

	Female ¹	Male	0-23 months			2-4 years			5-11 years			12-17 years		
Dosage			Unk.	>3 µg	≤3 µg	Unk.	>3 µg	≤ 3µg	Unk.	> 10µg	≤ 10 µg	Unk.	> 30µg	≤ 30µg
Local	774/1537 (50.4)	696/1526 (45.6)	1/4 (25.0)	86/296 (29.1)	22/68 (32.4)	5/12 (41.7)	354/837 (42.3)	33/102 (32.4)	141/286 (49.3)	42/69 (60.9)	559/1016 (55.0)	70/120 (58.3)	0/0 (0.0)	157/253 (62.1)
Fever	78/1550 (5.0)	71/1537 (4.6)	0/4 (0.0)	9/297 (3.0)	2/68 (2.9)	0/12 (0.0)	35/843 (4.2)	2/103 (1.9)	16/291 (5.5)	3/69 (4.3)	45/1021 (4.4)	11/122 (9.0)	0/0 (0.0)	26/257 (10.1)
General	260/1531 (17.0)	214/1518 (14.1)	0/4 (0.0)	35/295 (11.9)	6/68 (8.8)	1/12 (8.3)	93/832 (11.2)	3/101 (3.0)	53/286 (18.5)	16/69 (23.2)	142/1008 (14.1)	41/120 (34.2)	0/0 (0.0)	84/254 (33.1)
Musculoskeletal	90/1520 (5.9)	79/1518 (5.2)	0/4 (0.0)	2/296 (0.7)	0/68 (0.0)	0/12 (0.0)	27/827 (3.3)	1/101 (1.0)	18/285 (6.3)	11/69 (15.9)	55/1008 (5.5)	20/117 (17.1)	0/0 (0.0)	35/251 (13.9)
Gastrointestinal	24/1519 (1.6)	17/1514 (1.1)	0/4 (0.0)	5/296 (1.7)	0/68 (0.0)	0/12 (0.0)	9/829 (1.1)	0/100 (0.0)	6/284 (2.1)	1/68 (1.5)	13/1003 (1.3)	3/117 (2.5)	0/0 (0.0)	4/251 (1.6)
Otolaryngological	12/1513 (0.8)	12/1508 (0.8)	0/4 (0.0)	0/295 (0.0)	0/68 (0.0)	0/11 (0.0)	6/823 (0.7)	0/101 (0.0)	4/281 (1.4)	0/69 (0.0)	4/1005 (0.4)	3/118 (2.6)	0/0 (0.0)	7/247 (2.8)
Pulmonary	7/1519 (0.5)	5/1512 (0.3)	0/4 (0.0)	1/296 (0.3)	0/68 (0.0)	0/12 (0.0)	4/827 (0.5)	0/101 (0.0)	0/282 (0.0)	0/69 (0.0)	1/1005 (0.1)	2/118 (1.7)	0/0 (0.0)	4/250 (1.6)
Cardiovascular	6/1518 (0.4)	11/1510 (0.7)	0/4 (0.0)	0/296 (0.0)	0/67 (0.0)	0/12 (0.0)	1/824 (0.1)	0/101 (0.0)	2/283 (0.7)	0/69 (0.0)	4/1005 (0.4)	6/118 (5.1)	0/0 (0.0)	4/249 (1.6)
Neurological	63/1517 (4.2)	50/1507 (3.3)	0/4 (0.0)	1/295 (0.3)	0/65 (0.0)	0/12 (0.0)	10/826 (1.2)	0/101 (0.0)	15/281 (5.3)	7/69 (10.1)	43/1004 (4.3)	12/118 (10.2)	0/0 (0.0)	25/249 (10.0)
Psychological	19/1518 (1.3)	7/1507 (0.5)	0/4 (0.0)	5/296 (1.7)	0/67 (0.0)	0/12 (0.0)	1/824 (0.1)	0/101 (0.0)	2/281 (0.7)	1/68 (1.5)	9/1006 (0.9)	5/117 (4.3)	0/0 (0.0)	3/249 (1.2)
Dermatological	36/1516 (2.4)	31/1505 (2.1)	0/4 (0.0)	3/295 (1.0)	1/66 (1.5)	0/12 (0.0)	16/823 (1.9)	1/101 (1.0)	9/281 (3.2)	2/69 (2.9)	22/1003 (2.2)	3/118 (2.5)	0/0 (0.0)	10/249 (4.0)

¹and sex category *diverse*

eTable 4. Post-vaccination Symptoms After Third BNT162b2 Vaccine Dose, n/N (%)

	Female ¹	Male	0-23 months			2-4 years			5-11 years			12-17 years		
Dosage			Unk.	>3 µg	≤3 µg	Unk.	>3 µg	≤ 3µg	Unk.	> 10µg	≤ 10 µg	Unk.	> 30µg	≤ 30µg
Local	437/920 (47.5)	393/948 (41.5)	0/2 (0.0)	33/125 (26.4)	3/15 (20.0)	1/6 (16.7)	189/560 (33.8)	5/19 (26.3)	19/41 (46.3)	72/128 (56.3)	330/639 (51.6)	41/78 (52.6)	0/0 (0.0)	137/255 (53.7)
Fever	38/925 (4.1)	35/956 (3.7)	0/2 (0.0)	4/127 (3.1)	1/15 (6.7)	0/6 (0.0)	16/563 (2.8)	1/19 (5.3)	5/41 (12.2)	4/129 (3.1)	20/642 (3.1)	4/78 (5.1)	0/0 (0.0)	18/259 (6.9)
General	123/918 (13.4)	92/945 (9.7)	0/2 (0.0)	13/125 (10.4)	2/15 (13.3)	1/6 (16.7)	32/559 (5.7)	1/19 (5.3)	9/41 (22.0)	11/127 (8.7)	66/635 (10.4)	19/78 (24.4)	0/0 (0.0)	61/256 (23.8)
Musculoskeletal	39/913 (4.3)	28/947 (3.0)	0/2 (0.0)	0/125 (0.0)	0/15 (0.0)	0/6 (0.0)	12/558 (2.2)	0/19 (0.0)	0/41 (0.0)	6/127 (4.7)	19/637 (3.0)	13/76 (16.7)	0/0 (0.0)	17/254 (6.7)
Gastrointestinal	5/913 (0.5)	8/945 (0.8)	0/2 (0.0)	1/125 (0.8)	0/15 (0.0)	0/6 (0.0)	6/558 (1.1)	0/19 (0.0)	1/41 (2.4)	1/127 (0.8)	1/635 (0.2)	0/76 (0.0)	0/0 (0.0)	3/254 (1.2)
Otolaryngological	5/910 (0.5)	9/943 (1.0)	0/2 (0.0)	0/124 (0.0)	0/15 (0.0)	0/6 (0.0)	2/556 (0.4)	0/19 (0.0)	1/41 (2.4)	1/127 (0.8)	5/636 (0.8)	1/76 (1.3)	0/0 (0.0)	4/251 (1.6)
Pulmonary	4/915 (0.4)	4/945 (0.4)	0/2 (0.0)	1/125 (0.8)	0/15 (0.0)	0/6 (0.0)	1/558 (0.2)	0/19 (0.0)	0/41 (0.0)	0/127 (0.0)	1/637 (0.2)	4/76 (5.3)	0/0 (0.0)	1/254 (0.4)
Cardiovascular	1/911 (0.1)	4/945 (0.4)	0/2 (0.0)	0/125 (0.0)	0/15 (0.0)	0/6 (0.0)	1/556 (0.2)	0/19 (0.0)	0/41 (0.0)	0/127 (0.0)	1/637 (0.2)	2/76 (2.6)	0/0 (0.0)	1/253 (0.4)
Neurological	27/912 (3.0)	26/944 (2.8)	0/2 (0.0)	1/124 (0.8)	0/15 (0.0)	0/6 (0.0)	3/557 (0.5)	0/19 (0.0)	1/40 (2.5)	5/125 (4.0)	16/638 (2.5)	3/76 (3.9)	0/0 (0.0)	24/254 (9.4)
Psychological	10/913 (1.1)	3/942 (0.3)	0/2 (0.0)	0/125 (0.0)	0/15 (0.0)	0/6 (0.0)	2/557 (0.4)	0/19 (0.0)	0/41 (0.0)	0/127 (0.0)	1/636 (0.2)	3/74 (4.1)	0/0 (0.0)	7/253 (2.8)
Dermatological	25/913 (2.7)	25/942 (2.7)	1/2 (50.0)	0/125 (0.0)	0/15 (0.0)	0/6 (0.0)	8/556 (1.4)	0/19 (0.0)	5/41 (12.2)	5/127 (3.9)	17/635 (2.7)	4/76 (5.3)	0/0 (0.0)	10/253 (4.0)

¹and sex category *diverse*

eTable 5. Post-vaccination Symptoms After Fourth BNT162b2 Vaccine Dose, n/N (%)

	Female ¹	Male	0-23 months			2-4 years			5-11 years			12-17 years		
Dosage			Unk.	>3 µg	≤3 µg	Unk.	>3 µg	≤ 3µg	Unk.	> 10µg	≤ 10 µg	Unk.	> 30µg	≤ 30µg
Local	42/468 (9.0)	37/504 (7.3)	1/2 (50.0)	3/49 (6.1)	0/1 (0.0)	1/9 (11.1)	18/279 (6.5)	1/5 (20.0)	3/16 (18.8)	19/255 (7.5)	20/208 (9.6)	1/4 (25.0)	0/0 (0.0)	12/144 (8.3)
General	17/467 (3.6)	15/506 (3.0)	0/2 (0.0)	4/49 (8.2)	0/1 (0.0)	0/9 (0.0)	10/279 (3.6)	0/5 (0.0)	0/16 (0.0)	11/254 (4.3)	2/209 (1.0)	1/4 (25.0)	0/0 (0.0)	4/145 (2.8)
Fever	6/471 (1.3)	4/510 (0.8)	0/2 (0.0)	1/50 (2.0)	0/1 (0.0)	0/9 (0.0)	6/281 (2.1)	0/5 (0.0)	0/16 (0.0)	3/257 (1.2)	0/211 (0.0)	0/4 (0.0)	0/0 (0.0)	0/145 (0.0)
Musculoskeletal	8/465 (1.7)	2/506 (0.4)	0/2 (0.0)	0/49 (0.0)	0/1 (0.0)	0/9 (0.0)	1/278 (0.4)	0/5 (0.0)	2/16 (12.5)	3/254 (1.2)	3/209 (1.4)	0/3 (0.0)	0/0 (0.0)	1/145 (0.7)
Gastrointestinal	2/466 (0.4)	1/504 (0.2)	0/2 (0.0)	0/49 (0.0)	0/1 (0.0)	1/9 (11.1)	0/278 (0.0)	0/5 (0.0)	0/16 (0.0)	1/253 (0.4)	1/208 (0.5)	0/4 (0.0)	0/0 (0.0)	0/145 (0.0)
Otolaryngological	0/465 (0.0)	1/502 (0.2)	0/2 (0.0)	0/48 (0.0)	0/1 (0.0)	0/8 (0.0)	0/277 (0.0)	0/5 (0.0)	0/16 (0.0)	0/254 (0.0)	1/208 (0.5)	0/4 (0.0)	0/0 (0.0)	0/144 (0.0)
Pulmonary	1/467 (0.2)	0/504 (0.0)	0/2 (0.0)	1/49 (2.0)	0/1 (0.0)	0/9 (0.0)	0/278 (0.0)	0/5 (0.0)	0/16 (0.0)	0/254 (0.0)	0/208 (0.0)	0/4 (0.0)	0/0 (0.0)	0/145 (0.0)
Cardiovascular	0/466 (0.0)	0/505 (0.0)	0/2 (0.0)	0/49 (0.0)	0/1 (0.0)	0/9 (0.0)	0/277 (0.0)	0/5 (0.0)	0/16 (0.0)	0/254 (0.0)	0/209 (0.0)	0/4 (0.0)	0/0 (0.0)	0/145 (0.0)
Neurological	0/466 (0.0)	1/503 (0.2)	0/2 (0.0)	0/49 (0.0)	0/1 (0.0)	0/9 (0.0)	0/277 (0.0)	0/5 (0.0)	0/16 (0.0)	0/253 (0.0)	1/208 (0.5)	0/4 (0.0)	0/0 (0.0)	0/145 (0.0)
Psychological	2/466 (0.4)	0/505 (0.0)	0/2 (0.0)	0/49 (0.0)	0/1 (0.0)	0/9 (0.0)	0/278 (0.0)	0/5 (0.0)	0/16 (0.0)	1/254 (0.4)	1/209 (0.5)	0/4 (0.0)	0/0 (0.0)	0/144 (0.0)
Dermatological	2/466 (0.4)	4/502 (0.8)	0/2 (0.0)	0/49 (0.0)	0/1 (0.0)	1/9 (11.1)	0/276 (0.0)	0/5 (0.0)	1/16 (6.3)	1/253 (0.4)	3/208 (1.4)	0/4 (0.0)	0/0 (0.0)	0/145 (0.0)

¹and sex category *diverse*

eTable 6. Post-vaccination Symptoms After Fifth BNT162b2 Vaccine Dose, n/N (%)

	Female ¹	Male	0-23 months			2-4 years			5-11 years			12-17 years		
Symptoms/ Dosage			Unk.	>3 µg	≤3 µg	Unk.	>3 µg	≤ 3µg	Unk.	> 10µg	≤ 10 µg	Unk.	> 30µg	≤ 30µg
Local	59/114 (51.8)	45/112 (40.2)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	1/2 (50.0)	18/51 (35.3)	0/1 (0.0)	0/0 (0.0)	31/58 (53.4)	30/65 (46.2)	0/0 (0.0)	0/0 (0.0)	24/40 (60.0)
General	18/114 (15.8)	15/112 (13.4)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	5/51 (9.8)	0/1 (0.0)	0/0 (0.0)	10/58 (17.2)	6/65 (9.2)	0/0 (0.0)	0/0 (0.0)	12/40 (30.0)
Fever	8/114 (7.0)	8/112 (7.1)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	4/51 (7.8)	0/1 (0.0)	0/0 (0.0)	6/58 (10.3)	3/65 (4.6)	0/0 (0.0)	0/0 (0.0)	3/40 (7.5)
Musculoskeletal	4/114 (3.5)	2/111 (1.8)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	1/50 (2.0)	0/1 (0.0)	0/0 (0.0)	3/58 (5.2)	0/65 (0.0)	0/0 (0.0)	0/0 (0.0)	2/40 (5.0)
Gastrointestinal	1/114 (0.9)	0/112 (0.0)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	0/51 (0.0)	0/1 (0.0)	0/0 (0.0)	0/58 (0.0)	1/65 (1.5)	0/0 (0.0)	0/0 (0.0)	0/40 (0.0)
Otolaryngological	0/113 (0.0)	2/111 (1.8)	0/1 (0.0)	0/7 (0.0)	0/0 (0.0)	0/2 (0.0)	1/51 (2.0)	0/1 (0.0)	0/0 (0.0)	1/58 (1.7)	0/65 (0.0)	0/0 (0.0)	0/0 (0.0)	0/39 (0.0)
Pulmonary	0/114 (0.0)	0/112 (0.0)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	0/51 (0.0)	0/1 (0.0)	0/0 (0.0)	0/58 (0.0)	0/65 (0.0)	0/0 (0.0)	0/0 (0.0)	0/40 (0.0)
Cardiovascular	1/114 (0.9)	0/112 (0.0)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	0/51 (0.0)	0/1 (0.0)	0/0 (0.0)	0/58 (0.0)	0/65 (0.0)	0/0 (0.0)	0/0 (0.0)	1/40 (2.5)
Neurological	3/114 (2.6)	4/112 (3.6)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	0/51 (0.0)	0/1 (0.0)	0/0 (0.0)	2/58 (3.4)	3/65 (4.6)	0/0 (0.0)	0/0 (0.0)	2/40 (5.0)
Psychological	1/114 (0.9)	1/112 (0.9)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	0/51 (0.0)	0/1 (0.0)	0/0 (0.0)	0/58 (0.0)	1/65 (1.5)	0/0 (0.0)	0/0 (0.0)	1/40 (2.5)
Dermatological	5/113 (4.4)	3/112 (2.7)	0/1 (0.0)	0/8 (0.0)	0/0 (0.0)	0/2 (0.0)	2/51 (3.9)	0/1 (0.0)	0/0 (0.0)	3/58 (5.2)	1/64 (1.6)	0/0 (0.0)	0/0 (0.0)	2/40 (5.0)

¹and sex category *diverse*

eTable 7. Post-vaccination Symptoms After Sixth BNT162b2 Vaccine Dose, n/N (%)

	Female ¹	Male	0-23 months			2-4 years			5-11 years			12-17 years		
Symptoms/ Dosage			Unk.	>3 µg	≤3 µg	Unk.	>3 µg	≤ 3µg	Unk.	> 10µg	≤ 10 µg	Unk.	> 30µg	≤ 30µg
Local	9/16 (56.3)	5/19 (26.3)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	1/8 (12.5)	0/0 (0.0)	0/0 (0.0)	5/13 (38.5)	6/9 (66.7)	0/0 (0.0)	0/0 (0.0)	2/5 (40.0)
General	2/16 (12.5)	3/19 (15.8)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	2/13 (15.4)	1/9 (11.1)	0/0 (0.0)	0/0 (0.0)	2/5 (40.0)
Fever	1/16 (6.3)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	1/13 (7.7)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Musculo- skeletal	2/16 (12.5)	1/19 (5.3)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	1/8 (12.5)	0/0 (0.0)	0/0 (0.0)	1/13 (7.7)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	1/5 (20.0)
Gastro- intestinal	0/16 (0.0)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Otolaryngo- logical	0/16 (0.0)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Pulmonary	0/16 (0.0)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Cardio- vascular	0/16 (0.0)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Neurological	0/16 (0.0)	1/19 (5.3)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	1/9 (11.1)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Psycho- logical	1/16 (6.3)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	1/9 (11.1)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)
Dermato- logical	0/16 (0.0)	0/19 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/8 (0.0)	0/0 (0.0)	0/0 (0.0)	0/13 (0.0)	0/9 (0.0)	0/0 (0.0)	0/0 (0.0)	0/5 (0.0)

¹and sex category *diverse*

eTable 8. Local symptoms²

Symptom	Redness at the injection site	Swelling at the injection site	Pain at the injection site	Other local discomfort
After any vac.	741/3228 (23.0)	631/3228 (19.5)	1603/3228 (49.7)	42/3228 (1.3)
After 1 st vac.	619/3204 (19.3)	507/3204 (15.8)	1298/3204 (40.5)	29/3204 (0.9)
After 2 nd vac.	553/3120 (17.7)	427/3120 (13.7)	1199/3120 (38.4)	23/3120 (0.7)
After 3 rd vac.	271/1898 (14.3)	219/1898 (11.5)	685/1898 (36.1)	18/1898 (0.9)
After 4 th vac.	37/1003 (3.7)	26/1003 (2.6)	53/1003 (5.3)	2/1003 (0.2)
After 5 th vac.	26/227 (11.5)	21/227 (9.3)	90/227 (39.6)	1/227 (0.4)
After 6 th vac.	6/36 (16.7)	0/36 (0.0)	8/36 (22.2)	1/36 (2.8)
<i>Beginning & duration</i>				
Beginning (days after vaccination, mean ± SD/N)	1.5±0.6/731	1.6±0.7/612	1.5±0.2/1570	2.3±2.8/37
Duration (days, mean ±SD/N)	1.9±1.5/634	2.2±4.2/549	1.6±1.3/1423	2±1.6/36
≥90 days	0/741 (0.0)	0/631 (0.0)	0/1603 (0.0)	0/42 (0.0)
<i>Disposition</i>				
Rest	123/741 (16.6)	138/631 (21.9)	378/1603 (23.6)	17/42 (40.5)
Ambulatory	2/741 (0.3)	1/631 (0.2)	0/1603 (0.0)	0/42 (0.0)
Medication	0/0 (0.0)	0/0 (0.0)	73/1603 (4.5)	0/0 (0.0)
Inpatient	0/741 (0.0)	0/631 (0.0)	0/1603 (0.0)	0/42 (0.0)
Mortality	0/741 (0.0)	0/631 (0.0)	0/1603 (0.0)	0/42 (0.0)
Other	9/741 (1.2)	10/631 (1.6)	16/631 (1.0)	2/42 (4.8)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTable 9. General symptoms²

Symptom	Fever	Chills	Hot flashes	Fatigue	Flu-like symptoms	Feeling of weakness	Malaise/general feeling of illness	PIMS	Other general complaints
After any vac.	368/3228 (11.4)	71/3228 (2.2)	20/3228 (0.6)	649/3228 (20.1)	167/3228 (5.2)	194/3228 (6.0)	258/3228 (8.0)	0/3228 (0.0)	40/3228 (1.2)
After 1 st vac.	195/3204 (6.1)	42/3204 (1.3)	14/3204 (0.4)	462/3204 (14.4)	90/3204 (2.8)	133/3204 (4.2)	153/3204 (4.8)	0/3204 (0.0)	17/3204 (0.5)
After 2 nd vac.	152/3120 (4.9)	32/3120 (1.0)	11/3120 (0.4)	392/3120 (12.6)	77/3120 (2.5)	117/3120 (3.8)	139/3120 (4.5)	0/3120 (0.0)	18/3120 (0.6)
After 3 rd vac.	73/1898 (3.8)	15/1898 (0.8)	4/1898 (0.2)	171/1898 (9.0)	39/1898 (2.1)	50/1898 (2.6)	67/1898 (3.5)	0/1898 (0.0)	8/1898 (0.4)
After 4 th vac.	10/1003 (1.0)	0/1003 (0.0)	0/1003 (0.0)	28/1003 (2.8)	2/1003 (0.2)	2/1003 (0.2)	5/103 (0.5)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	16/227 (7.0)	4/227 (1.8)	1/227 (0.4)	20/227 (8.8)	8/227 (3.5)	7/227 (3.1)	13/227 (5.7)	0/227 (0.0)	2/227 (0.9)
After 6 th vac.	1/36 (2.8)	1/36 (2.8)	0/36 (0.0)	4/36 (11.1)	1/36 (2.8)	0/36 (0.0)	2/36 (5.6)	0/36 (0.0)	0/36 (0.0)
Beginning & duration									
Beginning (days after vaccination, mean ± SD/N)	1.7±2/367	1.6±0.5/69	1.5±0/20	1.6±0.77/646	1.9±2.7/165	1.7±0.85/193	1.5±0.4/254	0±0/0	2.4±5.4/39
Duration (days, mean ±SD/N)	1.2±1.2/322	1.2±1/55	1.8±1.3/19	1.8±3.1/555	2.8±2.8/131	2.2±3.2/176	2.0±3.5/226	0±0/0	5.7±17.2/35
≥90 days	0/368 (0.0)	0/71 (0.0)	0/20 (0.0)	1/649 (0.2)	0/167 (0.0)	0/194 (0.0)	0/258 (0.0)	0/0 (0.0)	0/40 (0.0)
Disposition									
Rest	260/368 (70.7)	54/71 (76.1)	18/20 (90.0)	451/649 (69.5)	135/167 (80.8)	162/194 (83.5)	198/258 (76.7)	0/0 (0.0)	24/40 (60.0)
Ambulatory	10/368 (2.7)	2/71 (2.8)	0/20 (0.0)	6/649 (0.9)	8/167 (4.8)	7/194 (3.6)	3/258 (1.2)	0/0 (0.0)	3/40 (7.5)
Medication	195/368 (53.0)	33/71 (46.5)	7/20 (35.0)	0/0 (0.0)	72/167 (43.1)	0/0 (0.0)	56/258 (21.7)	0/0 (0.0)	9/40 (22.5)
Inpatient	0/368 (0.0)	0/71 (0.0)	0/20 (0.0)	0/649 (0.0)	0/167 (0.0)	0/194 (0.0)	0/258 (0.0)	0/0 (0.0)	0/40 (0.0)
Mortality	0/368 (0.0)	0/71 (0.0)	0/20 (0.0)	0/649 (0.0)	0/167 (0.0)	0/194 (0.0)	0/258 (0.0)	0/0 (0.0)	0/40 (0.0)
Other	3/368 (0.8)	0/71 (0.0)	0/20 (0.0)	1/649 (0.2)	0/167 (0.0)	0/194 (0.0)	1/258 (0.4)	0/0 (0.0)	5/40 (12.5)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTable 10. Musculoskeletal symptoms²

Symptom	Muscle weakness	Muscle pain	Muscle twitching	Neck/back pain	Pain in the arms	Pain in the legs	Joint pain	Joint swelling	Pain in the limbs	Other complaints
After any vac.	20/3228 (0.6)	97/3228 (3.0)	1/3228 (0.0)	15/3228 (0.5)	129/3228 (4.0)	20/3228 (0.6)	23/3228 (0.7)	1/3228 (0.0)	49/3228 (1.5)	0/3228 (0.0)
After 1 st vac.	12/3204 (0.4)	64/3204 (2.0)	0/3204 (0.0)	8/3204 (0.2)	90/3204 (2.8)	10/3204 (0.3)	11/3204 (0.3)	0/3204 (0.0)	27/3204 (0.8)	0/3204 (0.0)
After 2 nd vac.	14/3120 (0.4)	74/3120 (2.4)	1/3120 (0.0)	7/3120 (0.2)	87/3120 (2.8)	14/3120 (0.4)	14/3120 (0.4)	1/3120 (0.0)	32/3120 (1.0)	0/3120 (0.0)
After 3 rd vac.	5/1898 (0.3)	28/1898 (1.5)	0/1898 (0.0)	3/1898 (0.2)	37/1898 (1.9)	3/1898 (0.2)	2/1898 (0.1)	0/1898 (0.0)	7/1898 (0.4)	0/1898 (0.0)
After 4 th vac.	0/1003 (0.0)	1/1003 (0.1)	0/1003 (0.0)	0/1003 (0.0)	7/1003 (0.7)	0/1003 (0.0)	2/1003 (0.2)	0/1003 (0.0)	1/1003 (0.1)	0/1003 (0.0)
After 5 th vac.	0/227 (0.0)	3/227 (1.3)	0/227 (0.0)	0/227 (0.0)	3/227 (1.3)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	0/36 (0.0)	1/36 (2.8)	0/36 (0.0)	0/36 (0.0)	3/36 (8.3)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
Beginning & duration										
Beginning (days after vaccination, mean ± SD/N)	5.7±12.8/19	2±4.2/94	0±0/0	2.1±1.5/13	1.5±0.3/128	1.5±0.0/18	2.7±3.7/20	1.5±0/1	1.8±1/44	0±0/0
Duration (days, mean ±SD/N)	6.7±8.1/18	2.8±3.1/85	0±0/0	2.6±2/11	2.7±2.3/111	4.2±3.9/17	6±8.2/17	0±0/0	4.1±4.5/34	0±0/0
≥90 days	0/20 (0.0)	0/97 (0.0)	0/1 (0.0)	0/15 (0.0)	0/129 (0.0)	1/20 (5.0)	0/23 (0.0)	0/1 (0.0)	1/42 (2.0)	0/0 (0.0)
Disposition										
Rest	18/20 (90.0)	56/97 (57.7)	0/1 (0.0)	13/15 (86.7)	68/129 (52.7)	15/20 (75.0)	18/23 (78.3)	0/1 (0.0)	38/49 (77.6)	0/0 (0.0)
Ambulatory	4/20 (20.0)	3/97 (3.1)	0/1 (0.0)	0/15 (0.0)	1/129 (0.8)	3/20 (15.0)	2/23 (8.7)	0/1 (0.0)	2/49 (4.1)	0/0 (0.0)
Medication	0/0 (0.0)	16/97 (16.5)	0/0 (0.0)	8/15 (0.0)	17/129 (13.2)	6/20 (30.0)	10/23 (43.5)	1/1 (100.0)	19/49 (38.8)	0/0 (0.0)
Inpatient	1/20 (5.0)	1/97 (1.0)	0/1 (0.0)	0/15 (0.0)	0/129 (0.0)	0/20 (0.0)	0/23 (0.0)	0/1 (0.0)	0/49 (0.0)	0/0 (0.0)
Mortality	0/20 (0.0)	0/97 (0.0)	0/1 (0.0)	0/15 (0.0)	0/129 (0.0)	0/20 (0.0)	0/23 (0.0)	0/1 (0.0)	0/49 (0.0)	0/0 (0.0)
Other	0/20 (0.0)	1/97 (1.0)	0/1 (0.0)	0/15 (0.0)	0/129 (0.0)	0/20 (0.0)	0/23 (0.0)	0/1 (0.0)	0/49 (0.0)	0/0 (0.0)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTable 11. Gastrointestinal symptoms²

Symptom	Abdominal pain	Nausea/vomiting	Constipation	Diarrhea	Other stool changes	Unwanted weight loss	Unwanted weight gain	Other gastrointestinal complaints
After any vac.	25/3228 (0.8)	51/3228 (1.6)	5/3228 (0.1)	18/3228 (0.6)	5/3228 (0.2)	3/3228 (0.1)	1/3228 (0.0)	3/3228 (0.1)
After 1 st vac.	15/3204 (0.5)	25/3204 (0.8)	3/3204 (0.1)	6/3204 (0.2)	1/3204 (0.0)	0/3204 (0.0)	0/3204 (0.0)	0/3204 (0.0)
After 2 nd vac.	15/3120 (0.5)	26/3120 (0.8)	2/3120 (0.1)	8/3120 (0.3)	0/3120 (0.0)	2/3120 (0.1)	0/3120 (0.0)	1/3120 (0.0)
After 3 rd vac.	3/1898 (0.2)	7/1898 (0.4)	0/1898 (0.0)	2/1898 (0.1)	0/1898 (0.0)	0/1898 (0.0)	1/1898 (0.0)	0/1898 (0.0)
After 4 th vac.	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	1/1003 (0.1)	2/1003 (0.2)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	0/227 (0.0)	1/227 (0.4)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
Beginning & duration								
Beginning (days after vaccination, mean ± SD/N)	6.92±11.15/24	2.73±6.19/43	3.5±2.83/2	3.75±5.46/16	1.5±0/4	3.5±2.83/2	0±0/0	1.5±0/2
Duration (days, mean ±SD/N)	9.79±20.3/19	1.05±1.62/43	47.5±60.1/2	3.13±3.14/15	1±0/2	25.5±6.36/2	0±0/0	17±28.58/3
≥90 days	1/25 (4.0)	0/51 (0.0)	0/5 (0.0)	1/18 (5.6)	0/5 (0.0)	0/3 (0.0)	1/1 (100.0)	0/3 (0.0)
Disposition								
Rest	14/25 (56.0)	36/51 (70.6)	0/5 (0.0)	9/18 (50.0)	0/5 (0.0)	2/3 (66.7)	0/1 (0.0)	1/3 (33.3)
Ambulatory	2/25 (8.0)	1/51 (2.0)	1/5 (20.0)	2/18 (11.1)	1/5 (20.0)	1/3 (33.3)	0/1 (0.0)	0/3 (0.0)
Medication								
Category 1 ³	7/25 (28.0)	2/51 (3.9)	0/5 (20.0)	1/18 (5.6)	0/5 (0.0)	0/3 (0.0)	0/1 (0.0)	0/3 (0.0)
Category 2 ⁴	6/25 (24.0)	4/51 (7.8)	1/5 (20.0)	4/18 (22.2)	1/5 (20.0)	1/3 (33.3)	0/1 (0.0)	0/3 (0.0)
Inpatient	1/25 (4.0)	0/51 (0.0)	0/5 (0.0)	0/18 (0.0)	0/5 (0.0)	0/3 (0.0)	0/1 (0.0)	1/3 (33.3)
Mortality	0/25 (0.0)	0/51 (0.0)	0/5 (0.0)	0/18 (0.0)	0/5 (0.0)	0/3 (0.0)	0/1 (0.0)	0/3 (0.0)
Other	1/25 (4.0)	0/51 (0.0)	1/5 (20.0)	1/18 (5.6)	0/5 (0.0)	1/3 (33.3)	0/1 (0.0)	0/3 (0.0)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

³Gastrointestinal medication, Antiemetics, Topical application of medication/ointments

⁴Analgetics, Antipyretics, Antiallergic drugs

eTable 12. Otolaryngological symptoms²

Symptom	Nosebleed	Redness of the oral mucosa	Swelling of the tongue	Swelling of the lips	Discomfort of the mouth	Too thache	Bleeding of the gums	Tightness in the throat	Sore throat	earache	Hoarseness	Facial swelling	Swollen lymph nodes	Painful lymph nodes	Olfactory disorder	Taste disorder	Other complaints
After any vac.	7/3228 (0.2)	3/3228 (0.1)	1/3228 (0.0)	1/3228 (0.0)	1/3228 (0.0)	0/3228 (0.0)	1/3228 (0.0)	1/3228 (0.0)	16/3228 (0.5)	5/3228 (0.2)	4/3228 (0.1)	0/3228 (0.0)	17/3228 (0.5)	6/3228 (0.2)	2/3228 (0.1)	3/3228 (0.1)	7/3228 (0.2)
After 1 st vac.	3/3204 (0.1)	2/3204 (0.1)	1/3204 (0.0)	1/3204 (0.0)	0/3204 (0.0)	0/3204 (0.0)	0/3204 (0.0)	0/3204 (0.0)	8/3204 (0.2)	2/3204 (0.1)	2/3204 (0.1)	0/3204 (0.0)	9/3204 (0.3)	2/3204 (0.1)	1/3204 (0.0)	2/3204 (0.1)	1/3204 (0.0)
After 2 nd vac.	4/3120 (0.1)	1/3120 (0.0)	0/3120 (0.0)	0/3120 (0.0)	1/3120 (0.0)	0/3120 (0.0)	0/3120 (0.0)	1/3120 (0.0)	7/3120 (0.2)	3/3120 (0.1)	4/3120 (0.1)	0/3120 (0.0)	9/3120 (0.3)	5/3120 (0.2)	1/3120 (0.0)	2/3120 (0.1)	2/3120 (0.1)
After 3 rd vac.	2/1898 (0.1)	1/1898 (0.1)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	1/1898 (0.1)	0/1898 (0.0)	5/1898 (0.3)	0/1898 (0.0)	1/1898 (0.1)	0/1898 (0.0)	3/1898 (0.2)	3/1898 (0.2)	1/1898 (0.1)	1/1898 (0.1)	3/1898 (0.2)
After 4 th vac.	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	1/1003 (0.1)	1/1003 (0.1)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	1/227 (0.4)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	1/227 (0.4)
After 6 th vac.	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
<i>Beginning & duration</i>																	
Beginning (days after vaccination, mean ± SD/N)	14.4±16.5/5	1.5±0.0/3	1.5±0.0/1	1.5±0.0/1	1.5±0.0/1	0±0/0	1.5±0.0/1	1.5±0.0/1	2±1.4/16	2.3±1.8/5	2.5±2/4	0±0/0	2±1.4/15	1.5±0/6	1.5±0/2	2.8±2.3/3	1.5±0/5

Symptom	Nosebleed	Redness of the oral mucosa	Swelling of the tongue	Swelling of the lips	Discomfort of the mouth	Toothache	Bleeding of the gums	Tightness in the throat	Sore throat	earache	Hoarseness	Facial swelling	Swollen lymph nodes	Painful lymph nodes	Olfactory disorder	Taste disorder	Other complaints
Duration (days, mean $\pm$ SD/N)	0.7 $\pm$ 1.5 0/7	4.7 $\pm$ 4.7/3	2 $\pm$ 0/1	2 $\pm$ 0/1	3 $\pm$ 0/1	0 $\pm$ 0/0	7 $\pm$ 0/1	7 $\pm$ 0/1	4.3 $\pm$ 3.3/16	4 $\pm$ 3/3	4 $\pm$ 2.4/4	0 $\pm$ 0/0	4.8 $\pm$ 3.3/14	5.3 $\pm$ 4.7/6	3 $\pm$ 0/2	4 $\pm$ 1/3	16.2 $\pm$ 24.7/5
$\geq$ 90 days	0/7 (0.0)	0/3 (0.0)	0/1 (0.0)	0/1 (0.0)	0/1 (0.0)	0/0 (0.0)	0/1 (0.0)	0/1 (0.0)	0/16 (0.0)	1/5 (20.0)	0/4 (0.0)	0/0 (0.0)	1/17 (6.0)	0/6 (0.0)	0/2 (0.0)	0/3 (0.0)	1/7 (14.0)
Disposition																	
Rest	2/7 (28.6)	0/3 (0.0)	1/1 (100.0)	0/1 (0.0)	0/1 (0.0)	0/0 (0.0)	0/1 (0.0)	1/1 (100.0)	15/16 (93.8)	2/5 (40.0)	4/4 (100.0)	0/0 (0.0)	10/17 (58.8)	5/6 (83.3)	0/2 (0.0)	0/3 (0.0)	3/7 (42.9)
Ambulatory	0/7 (0.0)	2/3 (66.7)	0/1 (0.0)	1/1 (100.0)	0/1 (0.0)	0/0 (0.0)	1/1 (100.0)	0/1 (0.0)	0/16 (0.0)	2/5 (40.0)	0/4 (0.0)	0/0 (0.0)	1/17 (5.9)	0/6 (0.0)	0/2 (0.0)	0/3 (0.0)	1/7 (14.3)
Medication	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/1 (0.0)	0/0 (0.0)	0/1 (0.0)	1/1 (100.0)	9/16 (56.2)	4/5 (80.0)	2/4 (50.0)	0/0 (0.0)	5/17 (29.4)	3/6 (50.0)	0/0 (0.0)	0/0 (0.0)	2/7 (28.6)
Inpatient	0/7 (0.0)	0/3 (0.0)	0/1 (0.0)	0/1 (0.0)	0/1 (0.0)	0/0 (0.0)	0/1 (0.0)	0/1 (0.0)	0/16 (0.0)	0/5 (0.0)	0/4 (0.0)	0/0 (0.0)	0/17 (0.0)	0/6 (0.0)	0/2 (0.0)	0/3 (0.0)	0/7 (0.0)
Mortality	0/7 (0.0)	0/3 (0.0)	0/1 (0.0)	0/1 (0.0)	0/1 (0.0)	0/0 (0.0)	0/1 (0.0)	0/1 (0.0)	0/16 (0.0)	0/5 (0.0)	0/4 (0.0)	0/0 (0.0)	0/17 (0.0)	0/6 (0.0)	0/2 (0.0)	0/3 (0.0)	0/7 (0.0)
Other	1/7 (14.3)	0/3 (0.0)	0/1 (0.0)	0/1 (0.0)	0/1 (0.0)	0/0 (0.0)	0/1 (0.0)	0/1 (0.0)	0/16 (0.0)	0/5 (0.0)	0/4 (0.0)	0/0 (0.0)	1/17 (5.9)	0/6 (0.0)	0/2 (0.0)	0/3 (0.0)	1/7 (14.3)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTable 13. Pulmonary symptoms²

Symptom	Cough	Irregular breathing	Rapid breathing	Shortness of breath on exertion	Dyspnea at rest	Other breathing problems
After any vac.	24/3228 (0.7)	0/3228 (0.0)	3/3228 (0.1)	10/3228 (0.3)	3/3228 (0.1)	2/3228 (0.1)
After 1 st vac.	11/3204 (0.3)	0/3204 (0.0)	2/3204 (0.1)	4/3204 (0.1)	3/3204 (0.1)	1/3204 (0.0)
After 2 nd vac.	7/3120 (0.2)	0/3120 (0.0)	0/3120 (0.0)	5/3120 (0.2)	2/3120 (0.1)	0/3120 (0.0)
After 3 rd vac.	5/1898 (0.3)	0/1898 (0.0)	0/1898 (0.0)	3/1898 (0.2)	0/1898 (0.0)	1/1898 (0.1)
After 4 th vac.	1/1003 (0.1)	0/1003 (0.0)	1/1003 (0.1)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
Beginning & duration						
Beginning (days after vaccination, mean $\pm$ SD/N)	7.6 $\pm$ 11.5/22	0 $\pm$ 0/0	1.5 $\pm$ 0/3	9.2 $\pm$ 11.8/9	6.8 $\pm$ 9.2/3	23.7 $\pm$ 25.8/2
Duration (days, mean $\pm$ SD/N)	7.1 $\pm$ 7.1/13	0 $\pm$ 0/0	1 $\pm$ 0/2	9.7 $\pm$ 12.3/7	0.5 $\pm$ 0.7/2	5 $\pm$ 2.8/2
$\geq$ 90 days	3/24 (12.5)	0/0 (0.0)	0/3 (0.0)	1/10 (10.0)	0/3 (0.0)	0/2 (0.0)
Disposition						
Rest	13/24 (54.2)	0/0 (0.0)	3/3 (100.0)	9/10 (90.0)	3/3 (100.0)	1/2 (50.0)
Ambulatory	3/24 (12.5)	0/0 (0.0)	0/3 (0.0)	0/10 (0.0)	0/3 (0.0)	0/2 (0.0)
Medication						
Category 1 ³	11/24 (45.8)	0/0 (0.0)	0/0 (0.0)	2/10 (20.0)	1/3 (33.3)	0/2 (0.0)
Category 2 ⁴	9/24 (37.5)	0/0 (0.0)	1/3 (33.3)	3/10 (30.0)	1/3 (33.3)	0/2 (0.0)
Inpatient	0/24 (0.0)	0/0 (0.0)	0/3 (0.0)	0/10 (0.0)	0/3 (0.0)	1/2 (50.0)
Mortality	0/24 (0.0)	0/0 (0.0)	0/3 (0.0)	0/10 (0.0)	0/3 (0.0)	0/2 (0.0)
Other	1/24 (4.2)	0/0 (0.0)	0/3 (0.0)	1/10 (10.0)	0/3 (0.0)	0/2 (0.0)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

³Oral Medication e.g. cough syrup

⁴Analgetics, Antipyretics, Antiallergic drugs, Inhalatives

eTable 14. Cardiovascular symptoms²

Symptom	Syncope	Tachycardia	Heart pain	Chest tightness	Cold hands and feet	Discoloration of hands/feet	Thrombosis/ Embolism	Other
After any vac.	9/3228 (0.3)	11/3228 (0.3)	10/3228 (0.3)	4/3228 (0.1)	5/3228 (0.2)	1/3228 (0.0)	0/3228 (0.0)	2/3228 (0.1)
After 1 st vac.	6/3204 (0.2)	6/3204 (0.2)	4/3204 (0.1)	3/3204 (0.1)	3/3204 (0.1)	1/3204 (0.0)	0/3204 (0.0)	1/3204 (0.0)
After 2 nd vac.	2/3120 (0.1)	8/3120 (0.3)	5/3120 (0.2)	0/3120 (0.0)	2/3120 (0.1)	1/3120 (0.0)	0/3120 (0.0)	1/3120 (0.0)
After 3 rd vac.	1/1898 (0.1)	3/1898 (0.2)	1/1898 (0.1)	0/1898 (0.0)	1/1898 (0.1)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)
After 4 th vac.	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	1/227 (0.4)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
<i>Beginning & duration</i>								
Beginning (days after vaccination, mean ± SD/N)	3.7±5.3/9	5.5±6.9/9	10±8.1/8	29.7±14.1/4	11.6±20.2/4	1.5±0/1	0±0/0	9.5±11.3/2
Duration (days, mean ±SD/N)	1.3±2.8/6	4.9±7.4/9	20.6±34.5/8	41.3±32.3/3	4.7±2.9/3	0±0/0	0±0/0	3±0/1
≥90 days	0/9 (0.0)	2/11 (18.2)	1/10 (10.0)	1/4 (25.0)	2/5 (40.0)	0/1 (0.0)	0/0 (0.0)	0/3 (0.0)
<i>Disposition</i>								
Rest	5/9 (55.6)	9/11 (81.8)	4/10 (40.0)	2/4 (50.0)	3/5 (60.0)	0/1 (0.0)	0/0 (0.0)	1/3 (33.3)
Ambulatory	3/9 (33.3)	2/11 (18.2)	5/10 (50.0)	2/4 (50.0)	0/5 (0.0)	0/1 (0.0)	0/0 (0.0)	0/3 (0.0)
Medication	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/4 (0.0)	0/0 (0.0)	0/1 (0.0)	0/0 (0.0)	0/3 (0.0)
Inpatient	0/9 (0.0)	0/11 (0.0)	0/10 (0.0)	0/4 (0.0)	0/5 (0.0)	0/1 (0.0)	0/0 (0.0)	0/3 (0.0)
Mortality	0/9 (0.0)	0/11 (0.0)	0/10 (0.0)	0/4 (0.0)	0/5 (0.0)	0/1 (0.0)	0/0 (0.0)	0/3 (0.0)
Other	1/9 (11.1)	0/11 (0.0)	1/10 (10.0)	1/4 (25.0)	0/5 (0.0)	1/1 (100.0)	0/0 (0.0)	1/3 (33.3)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTable 15. Neurological symptoms²

Symptom	Headache	Dizziness	Sensory disturbance	Locomotor disorders	Loss of consciousness	Shooting pain	Convulsive seizure	Paralysis of facial muscles	Other complaints
After any vac.	210/3228 (6.5)	46/3228 (1.4)	4/3228 (0.1)	0/3228 (0.0)	2/3228 (0.1)	2/3228 (0.1)	0/3228 (0.0)	0/3228 (0.0)	2/3228 (0.1)
After 1 st vac.	132/3204 (4.1)	23/3204 (0.7)	3/3204 (0.1)	0/3204 (0.0)	1/3204 (0.0)	2/3204 (0.1)	0/3204 (0.0)	0/3204 (0.0)	2/3204 (0.1)
After 2 nd vac.	110/3120 (3.5)	26/3120 (0.8)	2/3120 (0.1)	0/3120 (0.0)	1/3120 (0.0)	2/3120 (0.1)	0/3120 (0.0)	0/3120 (0.0)	0/3120 (0.0)
After 3 rd vac.	49/1898 (2.6)	11/1898 (0.6)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)
After 4 th vac.	1/1003 (0.1)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	6/227 (2.6)	3/227 (1.3)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	1/36 (2.8)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
Beginning & duration									
Beginning (days after vaccination, mean ± SD/N)	2.4±5.2/205	5.1±10.4/44	14±18.3/3	0±0/0	9.5±11.3/2	9.5±11.3/2	0±0/0	0±0/0	3.5±2.8/2
Duration (days, mean ±SD/N)	1.7±3.0/166	3.9±6.1/36	31±51.1/3	0±0/0	0±0/1	46.5±61.5/2	0±0/0	0±0/0	2±0/1
≥90 days	6/210 (2.9)	1/46 (2.2)	1/4 (25.0)	0/0 (0.0)	0/2 (0.0)	0/2 (0.0)	0/0 (0.0)	0/0 (0.0)	1/2 (50.0)
Disposition									
Rest	131/210 (62.4)	41/46 (89.1)	3/4 (75.0)	0/0 (0.0)	2/2 (100.0)	1/2 (50.0)	0/0 (0.0)	0/0 (0.0)	1/2 (50.0)
Ambulatory	4/210 (1.9)	5/46 (10.9)	1/4 (25.0)	0/0 (0.0)	0/2 (0.0)	0/2 (0.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)
Medication	95/210 (45.2)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	1/2 (50.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)
Inpatient	2/210 (1.0)	1/46 (2.2)	1/4 (25.0)	0/0 (0.0)	0/2 (0.0)	0/2 (0.0)	0/0 (0.0)	0/0 (0.0)	1/2 (50.0)
Mortality	0/210 (0.0)	0/46 (0.0)	0/4 (0.0)	0/0 (0.0)	0/2 (0.0)	0/2 (0.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)
Other	2/210 (1.0)	2/46 (4.3)	2/4 (50.0)	0/0 (0.0)	1/2 (50.0)	1/2 (50.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTable 16. Psychological symptoms²

Symptom	Concentration disorders	Memory disorders	Sleep disorders	Aggressive behavior	Nervousness	Hyperactivity	Anxiousness	Sadness/depression	Mood swings	Other complaints
After any vac.	18/3228 (0.6)	4/3228 (0.1)	12/3228 (0.4)	3/3228 (0.1)	4/3228 (0.1)	10/3228 (0.3)	13/3228 (0.4)	14/3228 (0.4)	10/3228 (0.3)	5/3228 (0.2)
After 1 st vac.	6/3204 (0.2)	1/3204 (0.0)	4/3204 (0.1)	0/3204 (0.0)	2/3204 (0.1)	7/3204 (0.2)	4/3204 (0.1)	1/3204 (0.0)	3/3204 (0.1)	2/3204 (0.1)
After 2 nd vac.	7/3120 (0.2)	1/3120 (0.0)	5/3120 (0.2)	1/3120 (0.0)	3/3120 (0.1)	4/3120 (0.1)	9/3120 (0.3)	4/3120 (0.1)	3/3120 (0.1)	2/3120 (0.1)
After 3 rd vac.	5/1898 (0.3)	1/1898 (0.1)	4/1898 (0.2)	0/1898 (0.0)	1/1898 (0.1)	1/1898 (0.1)	1/1898 (0.1)	2/1898 (0.1)	3/1898 (0.2)	2/1898 (0.1)
After 4 th vac.	1/1003 (0.1)	0/1003 (0.0)	0/1003 (0.0)	1/1003 (0.1)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	2/1003 (0.2)	1/1003 (0.1)	0/1003 (0.0)
After 5 th vac.	1/227 (0.4)	0/227 (0.0)	1/227 (0.4)	0/227 (0.0)	0/227 (0.0)	1/227 (0.4)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	0/36 (0.0)	0/36 (0.0)	1/36 (2.8)	0/36 (0.0)	0/36 (0.0)	1/36 (2.8)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
Beginning & duration										
Beginning (days after vaccination, mean ± SD/N)	6.1±11/9	17.5±0/1	5.9±6.8/9	26.2±12.4/2	1.5±0/1	2.5±1.8/8	4.2±5.3/9	2.8±2.3/3	5.5±6.9/5	15.6±19.1/4
Duration (days, mean ±SD/N)	27.9±39.3/8	0±0/0	16.1±22.3/7	0±0/0	37±32.5/2	2±2.7/6	11.5±23.8/6	0±0/0	1±0/1	0.5±0.7/2
≥90 days	5/18 (27.8)	2/4 (50.0)	3/12 (25.0)	2/3 (66.7)	1/4 (25.0)	0/10 (0.0)	2/13 (15.4)	6/14 (42.8)	4/10 (40.0)	3/5 (60.0)
Disposition										
Rest	8/18 (44.4)	1/4 (25.0)	5/12 (41.7)	1/3 (33.3)	1/4 (25.0)	0/10 (0.0)	5/13 (38.5)	3/14 (21.4)	2/10 (20.0)	2/5 (40.0)
Ambulatory	3/18 (16.7)	1/4 (25.0)	0/12 (0.0)	0/3 (0.0)	0/4 (0.0)	0/10 (0.0)	1/13 (7.7)	7/14 (50.0)	1/10 (10.0)	1/5 (20.0)
Medication	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)	0/0 (0.0)
Inpatient	0/18 (0.0)	0/4 (0.0)	0/12 (0.0)	0/3 (0.0)	0/4 (0.0)	0/10 (0.0)	1/13 (7.7)	0/14 (0.0)	0/10 (0.0)	2/5 (40.0)
Mortality	0/18 (0.0)	0/4 (0.0)	0/12 (0.0)	0/3 (0.0)	0/4 (0.0)	0/10 (0.0)	0/13 (0.0)	0/14 (0.0)	0/10 (0.0)	0/5 (0.0)
Other	3/18 (16.7)	0/4 (0.0)	3/12 (25.0)	1/3 (33.3)	1/4 (25.0)	0/10 (0.0)	2/13 (15.4)	2/14 (14.3)	1/10 (10.0)	0/5 (0.0)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

eTabel 17. Skin Symptoms²

Symptom	Local rash	Rash all over the body	Swelling of lymph nodes	Painful lymph nodes	Extensive reddening of the skin	Other skin discoloration	Wheals/hives	Blister s with fluid/pu s	Petechiae	Hematoma	Dry skin	Skin eczema	Open skin areas	Itching	Other skin complaints
After any vac.	15/3228 (0.5)	6/3228 (0.2)	87/3228 (2.7)	58/3228 (1.8)	1/3228 (0.0)	0/3228 (0.0)	6/3228 (0.2)	2/3228 (0.1)	4/3228 (0.1)	0/3228 (0.0)	7/3228 (0.2)	4/3228 (0.1)	1/3228 (0.0)	8/3228 (0.2)	2/3228 (0.1)
After 1 st vac.	5/3204 (0.2)	4/3204 (0.1)	35/3204 (1.1)	22/3204 (0.7)	0/3204 (0.0)	0/3204 (0.0)	2/3204 (0.1)	2/3204 (0.1)	2/3204 (0.1)	0/3204 (0.0)	3/3204 (0.1)	0/3204 (0.0)	0/3204 (0.0)	2/3204 (0.1)	1/3204 (0.0)
After 2 nd vac.	8/3120 (0.3)	1/3120 (0.0)	42/3120 (1.3)	27/3120 (0.9)	1/3120 (0.0)	0/3120 (0.0)	3/3120 (0.1)	1/3120 (0.0)	1/3120 (0.0)	0/3120 (0.0)	6/3120 (0.2)	3/3120 (0.1)	1/3120 (0.0)	6/3120 (0.2)	1/3120 (0.0)
After 3 rd vac.	3/1898 (0.2)	0/1898 (0.0)	39/1898 (2.1)	29/1898 (1.5)	1/1898 (0.1)	0/1898 (0.0)	1/1898 (0.1)	0/1898 (0.0)	0/1898 (0.0)	0/1898 (0.0)	1/1898 (0.1)	0/1898 (0.0)	0/1898 (0.0)	1/1898 (0.1)	0/1898 (0.0)
After 4 th vac.	1/1003 (0.1)	0/1003 (0.0)	5/1003 (0.5)	4/1003 (0.4)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)	0/1003 (0.0)
After 5 th vac.	0/227 (0.0)	0/227 (0.0)	8/227 (3.5)	1/227 (0.4)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)	0/227 (0.0)
After 6 th vac.	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)	0/36 (0.0)
<i>Beginning & duration</i>															
Beginning (days after vaccination, mean $\pm$ SD/N)	10 $\pm$ 14.8/15	2.5 $\pm$ 2/4	2.1 $\pm$ 4.4/84	1.6 $\pm$ 0.7/58	1.5 $\pm$ 0/1	0 $\pm$ 0/0	16.2 $\pm$ 14.8/6	11.5 $\pm$ 8.5/2	12.7 $\pm$ 19.3/3	0 $\pm$ 0/0	6.5 $\pm$ 7.6/4	5.5 $\pm$ 0/1	35 $\pm$ 0/1	10.2 $\pm$ 15.7/6	0 $\pm$ 0/0
Duration (days, mean $\pm$ SD/N)	14.5 $\pm$ 27.4/11	5.4 $\pm$ 2.2/5	3.7 $\pm$ 2.9/76	3.8 $\pm$ 3/51	3 $\pm$ 0/1	0 $\pm$ 0/0	1.5 $\pm$ 1.5/6	3.5 $\pm$ 0.7/2	14 $\pm$ 0/1	0 $\pm$ 0/0	8.5 $\pm$ 2.1/2	90 $\pm$ 0/1	0 $\pm$ 0/0	36 $\pm$ 48.1/2	0 $\pm$ 0/0
≥ 90 days	2/15 (13.3)	0/6 (0.0)	1/87 (1.1)	0/58 (0.0)	0/1 (0.0)	0/0 (0.0)	0/6 (0.0)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	3/7 (42.8)	1/4 (25.0)	1/1 (100.0)	1/8 (12.5)	2/2 (100.0)

Symptom	Local rash	Rash all over the body	Swelling of lymph nodes	Painful lymph nodes	Extensive reddening of the skin	Other skin discoloration	Wheals/hives	Blister s with fluid/pus	Petechiae	Hematoma	Dry skin	Skin eczema	Open skin areas	Itching	Other skin complaints
Disposition															
Rest	1/15 (6.7)	2/6 (33.3)	42/87 (48.3)	35/58 (0.0)	1/1 (100.0)	0/0 (0.0)	1/6 (16.7)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	1/7 (14.3)	0/4 (0.0)	0/1 (0.0)	0/8 (0.0)	0/2 (0.0)
Ambulatory	1/15 (6.7)	1/6 (16.7)	0/87 (0.0)	0/58 (0.0)	0/1 (0.0)	0/0 (0.0)	3/6 (50.0)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	0/7 (0.0)	0/4 (0.0)	0/1 (0.0)	0/8 (0.0)	2/2 (50.0)
Medication															
Category 1 ³	8/15 (53.3)	4/6 (66.7)	0/87 (0.0)	1/58 (1.7)	1/1 (100.0)	0/0 (0.0)	2/6 (33.3)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	5/7 (71.4)	4/4 (100.0)	1/1 (100.0)	6/8 (75.0)	1/2 (50.0)
Category 2 ⁴	4/15 (26.7)	4/6 (66.7)	8/87 (9.2)	10/58 (17.2)	0/1 (0.0)	0/0 (0.0)	5/6 (83.3)	0/2 (0.0)	1/4 (25.0)	0/0 (0.0)	2/7 (28.6)	0/4 (0.0)	0/1 (0.0)	3/8 (37.5)	0/2 (0.0)
Inpatient	0/15 (0.0)	0/6 (0.0)	0/87 (0.0)	0/58 (0.0)	0/1 (0.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	0/7 (0.0)	0/4 (0.0)	0/1 (0.0)	0/8 (0.0)	0/2 (0.0)
Mortality	0/15 (0.0)	0/6 (0.0)	0/87 (0.0)	0/58 (0.0)	0/1 (0.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	0/7 (0.0)	0/4 (0.0)	0/1 (0.0)	0/8 (0.0)	0/2 (0.0)
Other	0/15 (0.0)	1/6 (16.7)	35/58 (60.3)	0/58 (0.0)	0/1 (0.0)	0/0 (0.0)	0/0 (0.0)	0/2 (0.0)	0/4 (0.0)	0/0 (0.0)	0/7 (0.0)	0/4 (0.0)	0/1 (0.0)	0/8 (0.0)	0/2 (0.0)

²including individuals whose age at time of vaccination was unknown because of missing vaccination date (Table 1 Characteristics of the cohort related to the chronological BNT162b2 vaccinations one through six in the Paper)

³Topical application of medication/ointments

⁴Analgetics, Antipyretics, Antiallergic drugs

eTable 18. Post-vaccination Symptoms After Monovalent and Bivalent BNT162b2 n/N (%)

Age group	0-23 months		P (Fisher) ⁵	P (Fisher)	2-4 years		P (Fisher) ⁵	P (Fisher)	5-11 years		P (Fisher) ⁵	P (Fisher)	12-17 years		P (Fisher) ⁵	P (Fisher)
Vaccine variant	Mono-valent	Bi-valent			Mono-valent	Bi-valent			Mono-valent	Bi-valent			Mono-valent	Bi-valent		
A Post-Vaccination Symptoms After the Third Vaccination																
Any symptom reported	30/102 (29.4)	13/37 (35.1)	>0.99	0.54	172/467 (36.8)	44/112 (39.3)	>0.99	0.66	354/646 (54.8)	91/156 (58.3)	>0.99	0.47	184/300 (61.3)	13/22 (59.1)	>0.99	0.82
Local	25/102 (25.0)	9/37 (24.3)	>0.99	1.0	157/467 (33.8)	36/112 (32.1)	>0.99	0.82	329/646 (51.2)	87/156 (56.1)	>0.99	0.26	160/300 (54.1)	10/22 (45.5)	>0.99	0.51
General	10/102 (9.8)	4/37 (10.8)	>0.99	1.0	26/467 (5.6)	6/112 (5.4)	>0.99	1.0	75/646 (11.7)	10/156 (6.5)	>0.99	0.06	68/300 (22.9)	6/22 (27.3)	>0.99	0.61
Fever	1/102 (1.0)	3/37 (8.1)	0.72	0.06	14/467 (3.0)	3/112 (2.7)	>0.99	1.0	23/646 (3.6)	5/156 (3.2)	>0.99	1.0	18/300 (6.0)	2/22 (9.1)	>0.99	0.64
Musculoskeletal	0/102 (0.0)	0/37 (0.0)	NA	NA	8/467 (1.7)	3/112 (2.7)	>0.99	0.46	18/646 (2.8)	5/156 (3.3)	>0.99	0.79	26/300 (8.9)	2/22 (9.1)	>0.99	1.0
Gastrointestinal	1/102 (1.0)	0/37 (0.0)	>0.99	1.0	5/467 (1.1)	1/112 (0.9)	>0.99	1.0	2/646 (0.3)	1/156 (0.7)	>0.99	0.48	3/300 (1.0)	0/22 (0.0)	>0.99	1.0
Otolaryngological	0/102 (0.0)	0/37 (0.0)	NA	NA	1/467 (0.2)	1/112 (0.9)	>0.99	0.35	6/646 (0.9)	1/156 (0.7)	>0.99	1.0	3/300 (1.0)	1/22 (4.5)	>0.99	0.25
Pulmonary	0/102 (0.0)	1/37 (2.7)	>0.99	0.27	1/467 (0.2)	0/112 (0.0)	>0.99	1.0	1/646 (0.2)	0/156 (0.0)	>0.99	1.0	3/300 (1.0)	0/22 (0.0)	>0.99	1.0
Cardiovascular	0/102 (0.0)	0/37 (0.0)	NA	NA	1/467 (0.2)	0/112 (0.0)	>0.99	1.0	1/646 (0.2)	0/156 (0.0)	>0.99	1.0	2/300 (0.7)	0/22 (0.0)	>0.99	1.0
Neurological	1/102 (1.0)	0/37 (0.0)	>0.99	1.0	2/467 (0.4)	1/112 (0.9)	>0.99	0.48	17/646 (2.6)	4/156 (2.6)	>0.99	1.0	24/300 (8.2)	2/22 (9.1)	>0.99	0.70
Psychological	0/102 (0.0)	0/37 (0.0)	NA	NA	2/467 (0.4)	0/112 (0.0)	>0.99	1.0	1/646 (0.2)	0/156 (0.0)	>0.99	1.0	9/300 (3.1)	1/22 (4.5)	>0.99	0.52
Dermatological	0/102 (0.0)	1/37 (2.7)	>0.99	0.27	8/467 (1.7)	0/112 (0.0)	>0.99	0.37	22/646 (3.4)	5/156 (3.3)	>0.99	1.0	13/300 (4.4)	0/22 (0.0)	>0.99	0.61
B: Post-Vaccination Symptoms After the Fourth Vaccination																
Any symptom reported	0/7 (0.0)	4/31 (12.9)	>0.99	1.0	2/42 (4.8)	22/199 (11.1)	>0.99	0.27	12/64 (18.8)	38/367 (10.4)	0.72	0.06	2/35 (5.7)	13/102 (12.7)	>0.99	0.35
Local	0/6 (0.0)	3/31 (9.7)	>0.99	1.0	1/42 (2.4)	16/197 (8.1)	>0.99	0.32	10/63 (15.9)	28/364 (7.7)	0.6	0.05	2/35 (5.7)	10/101 (9.9)	>0.99	0.73

	0-23 months		P (Fisher) ⁵	P (Fisher)	2-4 years		P (Fisher) ⁵	P (Fisher)	5-11 years		P (Fisher) ⁵	P (Fisher)	12-17 years		P (Fisher) ⁵	P (Fisher)
Vaccine variant	Mono-valent	Bi-valent			Mono-valent	Bi-valent			Mono-valent	Bi-valent			Mono-valent	Bi-valent		
General	0/6 (0.0)	2/31 (6.5)	>0.99	1.0	0/42 (0.0)	9/197 (4.6)	>0.99	0.37	1/63 (1.6)	11/364 (3.0)	>0.99	1.0	0/35 (0.0)	5/102 (4.9)	>0.99	0.33
Fever	0/7 (0.0)	1/31 (3.2)	>0.99	1.0	0/42 (0.0)	5/199 (2.5)	>0.99	0.59	0/64 (0.0)	3/367 (0.8)	>0.99	1.0	0/35 (0.0)	0/103 (0.0)	NA	NA
Musculoskeletal	0/6 (0.0)	0/31 (0.0)	NA	NA	1/42 (2.4)	0/196 (0.0)	>0.99	0.18	2/63 (3.2)	6/364 (1.6)	>0.99	0.33	0/35 (0.0)	1/102 (1.0)	>0.99	0.74
Gastrointestinal	0/7 (0.0)	0/31 (0.0)	NA	NA	0/42 (0.0)	0/196 (0.0)	NA	NA	0/63 (0.0)	1/362 (0.3)	>0.99	1.0	0/35 (0.0)	0/102 (0.0)	NA	NA
Otolaryngological	0/6 (0.0)	0/31 (0.0)	NA	NA	0/42 (0.0)	0/195 (0.0)	NA	NA	0/62 (0.0)	1/364 (0.3)	>0.99	1.0	0/34 (0.0)	0/102 (0.0)	NA	NA
Pulmonary	0/6 (0.0)	1/31 (3.2)	>0.99	1.0	0/42 (0.0)	0/196 (0.0)	NA	NA	0/63 (0.0)	0/363 (0.0)	NA	NA	0/35 (0.0)	0/102 (0.0)	NA	NA
Cardiovascular	0/6 (0.0)	0/31 (0.0)	NA	NA	0/42 (0.0)	0/195 (0.0)	NA	NA	0/63 (0.0)	0/364 (0.0)	NA	NA	0/35 (0.0)	0/102 (0.0)	NA	NA
Neurological	0/6 (0.0)	0/31 (0.0)	NA	NA	0/42 (0.0)	0/195 (0.0)	NA	NA	0/62 (0.0)	1/363 (0.3)	>0.99	1.0	0/35 (0.0)	0/102 (0.0)	NA	NA
Psychological	0/6 (0.0)	0/31 (0.0)	NA	NA	0/42 (0.0)	0/196 (0.0)	NA	NA	0/63 (0.0)	2/364 (0.5)	>0.99	1.0	0/35 (0.0)	0/102 (0.0)	NA	NA
Dermatological	0/6 (0.0)	0/31 (0.0)	NA	NA	0/42 (0.0)	0/194 (0.0)	NA	NA	0/62 (0.0)	5/363 (1.4)	>0.99	1.0	0/35 (0.0)	0/102 (0.0)	NA	NA

⁵Adjusted for multiple testing by Bonferroni Correction

eTable 19. Active Comparator Analysis, Over All Age groups 0-17 years, n/N (%)

Variable	Frequencies, No./total No. (%)				Logistic regression	
	BNT162b2	(%)	Non-SARS-CoV-2	(%)	OR (95% CI)	P value
Disposition						
Physical rest	344/1185	29.0	196/1185	16.5	2.04 (1.67-2.50)	<0.001
Medication	133/1185	11.2	128/1185	10.8	0.80 (0.61-1.05)	0.79
Ambulatory	16/1185	1.4	2/1185	0.2	8.11 (1.86-35.37)	0.005
Inpatient	3/1185	0.3	1/1185	0.1	3.02 (0.31-29.11)	0.34
Mortality	0/1185	0.0	0/1185	0.0	N.A	N.A.
Symptoms						
Any symptom reported	832/1185	70.2	412/1185	34.8	4.42 (3.71-5.28)	<0.001
Local	748/1185	63.1	347/1185	29.3	4.25 (3.56-5.01)	<0.001
General	339/1185	28.7	229/1185	18.1	1.78 (1.46-2.17)	<0.001
Fever	139/1185	11.7	141/1185	11.9	0.97 (0.75-1.26)	0.84
Musculoskeletal	75/1185	6.3	27/1185	2.3	3.11 (1.95-4.99)	<0.001
Gastrointestinal	31/1185	2.6	10/1185	0.8	3.29 (1.55-6.99)	0.002
Otolaryngological	13/1185	1.1	3/1185	0.3	4.07 (1.15-14.50)	0.03
Pulmonary	10/1185	0.8	1/1185	0.1	10.11 (1.29-79.15)	0.03
Cardiovascular	10/1185	0.8	1/1185	0.1	9.35 (1.18-74.37)	0.03
Neurological	77/1185	6.5	7/1185	0.6	11.72 (5.34-25.74)	<0.001
Psychological	20/1185	1.7	2/1185	0.2	9.71 (2.25-41.81)	0.002
Dermatological	61/1185	5.2	9/1185	0.8	7.08 (3.49-14.36)	<0.001

eTable 20. Serious Adverse Events (SAE) and Characteristics of Children with reported SAE after BNT162b2 Vaccination, n/N (%)

	All Children		Children with reported SAE			
	Logistic regression for reporting a SAE including all individuals (N=3228)		Age Group			
	OR (95% CI)	p	0-23 months	2-4 years	5-11 years	12-17 years
Age (metric)	1.16 (0.96-1.41)	0.13				
Number of Children with reported SAE n/N (%)	45/3228 (1.4)		5/45 (11.1)	9/45 (20.0)	20/45 (44.4)	11/45 (24.4)
Sex categorie						
Female	4.55 (2.10-9.88)	<0.001	3/5 (60.0)	8/9 (88.9)	15/20 (75.0)	10/11 (90.9)
Male	Reference group		2/5 (40.0)	1/9 (11.1)	5/20 (25.0)	1/11 (9.1)
Divers			0/5 (0.0)	0/9 (0.0)	0/25 (0.0)	0/11 (0.0)
Comorbidities						
Any	0.40 (0.13-1.26)	0.12	1/5 (20.0)	0/9 (0.0)	4/20 (20.0)	0/11 (0.0)
Pulmonary			0/5 (0.0)	0/9 (0.0)	3/20 (15.0)	0/11 (0.0)
Oncological			0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Rheumatological			0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Gastrointestinal			0/5 (0.0)	0/9 (0.0)	1/20 (5.0)	0/11 (0.0)
Cardiovascular			0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Immunosuppression			0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Trisomie 21			0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Other comorbidities			1/5 (20.0)	0/9 (0.0)	2/20 (10.0)	0/11 (0.0)
Long- term medication						
Any	3.67 (1.39-9.69)	0.009	1/5 (20.0)	0/9 (0.0)	6/20 (30.0)	0/11 (0.0)
Analgetics			1/5 (20.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Antibiotics			1/5 (20.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)

		Age Group			
		0-23 months	2-4 years	5-11 years	12-17 years
Immunosuppressants		0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Diuretics		0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Inhalatives		1/5 (20.0)	0/9 (0.0)	1/20 (5.0)	0/11 (0.0)
Anticonvulsants		1/5 (20.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Aniticoagulants/ platelet aggregation inhibitors		0/5 (0.0)	0/9 (0.0)	0/20 (0.0)	0/11 (0.0)
Other medications		1/5 (20.0)	0/9 (0.0)	5/20 (25.0)	1/11 (9.1)
All Reported symptoms of children with reported SAE					
Local		3/5 (60.0)	6/9 (66.7)	12/19 (60.0)	8/11 (72.7)
General		1/5 (20.0)	6/9 (66.7)	8/20 (40.0)	7/11 (63.6)
Fever		1/5 (20.0)	2/9 (22.2)	4/20 (20.0)	4/11 (36.4)
Musculoskeletal		0/5 (0.0)	3/9 (33.3)	7/20 (35.0)	4/11 (36.4)
Gastrointestinal		1/5 (20.0)	2/9 (25.0)	2/20 (10.0)	2/11 (18.2)
Otolaryngological		0/5 (0.0)	1/9 (11.1)	2/19 (10.5)	1/10 (10.0)
Pulmonary		2/5 (40.0)	1/9 (11.1)	0/19 (0.0)	3/11 (27.3)
Cardiovascular		0/5 (0.0)	1/9 (11.1)	6/20 (30.0)	2/11 (18.2)
Neurological		1/5 (20.0)	5/9 (55.6)	6/20 (30.0)	7/11 (63.6)
Psychological		1/5 (20.0)	2/9 (22.2)	10/20 (50.0)	8/11 (72.7)
Dermatological		2/5 (40.0)	5/9 (55.6)	6/20 (30.0)	0/11 (0.0)

eTable 21. Characteristics of Children with reported Hospitalization after BNT162b2 Vaccination, n/N (%)

	All Children		Children with reported Hospitalization			
	Logistic regression for reporting a hospitalization including all individuals (N=3228)		Age Group			
	OR [95% CI]	p	0-23 months	2-4 years	5-11 years	12-17 years
Number of Individuals with reported hospitalization	6/3228 (0.2)		1/6 (16.6)	0/6 (0.0)	2/6 (33.3)	3/6 (50)
Reported Events of hospitalisation	7		1	0	2	4
Female	2.43 [0.47-12.64]	0.29	0/6 (0.0)	0/6 (0.0)	2/6 (33.3)	3/6 (50.0)
Male	Reference group		1/6 (16.6)	0/6 (0.0)	0/6 (0.0)	0/3 (0.0)
Comorbidities	NA	NA	0/6 (0.0)	0/6 (0.0)	0/6 (0.0)	0/6 (0.0)
Long-Term-Medication	NA	NA	0/6 (0.0)	0/6 (0.0)	0/6 (0.0)	0/6 (0.0)
Reported Symptoms in free text boxes			Obstructive bronchitis		Abdominal pain, nausea, Vomiting; Headache, dizziness, vomiting	Headache, dizziness, visual disturbance, sensory disorders, speech disorder; Abdominal lymph node swelling; Anxoius, eating disorders; Eating disorder
Beginning (days after vaccination, mean/N [min.; max.])			42/1 [42;42]	0/0 [0;0]	23/2 [4;42]	67/3 [4;42]
Duration (days, mean [min.; max.])			3/1 [3;3]	0/0 [0;0]	4/2 [2;6]	33/4 [1;100]

eTable 22. Counts of Missing Data, n/N (%)

	N = 3228
Female	0
Male	0
Divers	0
Age	0
Weight	81 (2.5)
Height	78 (2.4)
Comorbidities	0
Long-term Medication	4
Dosage	
1 st Vaccination	441 (13.8)
2 nd Vaccination	432 (13.8)
3 rd Vaccination	128 (6.7)
4 th Vaccination	31 (3.1)
5 th Vaccination	3 (1.3)
6 th Vaccination	0 (0.0)
Symptoms	
Duration	203 (6.3)
Local	31 (1.0)
General	47 (1.5)
Fever	0 (0.0)
Musculoskeletal	59 (1.8)
Gastrointestinal	65 (2.0)
Otolaryngological	77 (2.4)
Pulmonary	66 (2.0)
Cardiovascular	71 (2.2)
Neurological	74 (2.3)
Psychological	73 (2.3)
Dermatological	78 (2.4)
Threat rating scale	0 (0.0)